.jpg?20250817')
In the latest setback for Pfizer's sickle cell anaemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients aged 16 and older.
The trial results showed no significant difference in the number of vaso-occlusive crises — or painful events common in sickle cell disease — among people who took the drug versus those who took the placebo, the drugmaker said on Friday.
This makes inclacumab the second drug from Pfizer's 2022 acquisition of Global Blood Therapeutics to yield unfavourable results. Oxbryta - the centrepiece of the $5.4 billion buyout - was withdrawn last September over risks of painful complications and deaths.
"Pfizer's acquisition of Global Blood has proven disappointing with inclacumab's failure coming after Oxbryta's 2024 withdrawal from all approved markets" said BMO Capital Markets analyst Evan Seigerman.
The previously estimated $3 billion in revenue contributions from the deal now seems unlikely to materialise, Seigerman said.
Pfizer said it was disappointed by inclacumab's results but remains committed to supporting the sickle cell community.
The company will keep working on its sickle cell treatments, including Oxbryta and osivelotor, another therapy secured from the Global Blood deal.
Sickle cell anaemia is an inherited blood disorder in which red blood cells become sickle- or crescent-shaped and can cause strokes, organ damage and death.
Existing FDA-approved therapies for the genetic blood disorder include Vertex Pharmaceuticals' and CRISPR Therapeutics' Casgevy and Bluebird Bio's Lyfgenia.
&uuid=(email))